Immunology companies study and manipulate the immune system to develop therapies, diagnostics and research tools. The field plays a central role in areas such as cancer, infectious disease, autoimmune disorders and vaccine development.
This category includes companies working on:
Browse 182 UK immunology companies below.
Recombinant and native protein products for life science research
Creative BioMart is a biotechnology supplier of recombinant and native protein products for the research, diagnostics and biopharmaceutical communities. The company offers over 100,000 products, including cytokines, antibodies, antigens and cell and tissue lysates, alongside custom services such as protein expression,…
Small molecule drug discovery targeting rare genetic diseases and oncology
Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic…
Global pharma company in immunology, vaccines, and oncology
GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines.…
Antibodies, proteins and immunoassays for life science research
Proteintech Europe is the UK and European subsidiary of Proteintech Group, a US-based manufacturer of research reagents. The company produces antibodies, recombinant proteins, nanobodies and immunoassay kits for life science research, with a catalogue covering more than 13,000 protein targets. Additional product lines…
CRO specialising in oncology, inflammation and respiratory disease models
Axis Bioservices is a preclinical contract research organisation providing bespoke in vitro and in vivo study services for pharmaceutical, biotechnology and academic clients. Specialist capabilities span oncology tumour models, inflammatory disease models including rheumatoid arthritis and pulmonary fibrosis, and…
Fibroblast immunology platform targeting cancer and inflammatory disease
Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies that target activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a FAP-targeted LTBR agonist bispecific antibody designed to induce tertiary…
Small-molecule HO-1 inhibitors to overcome chemotherapy resistance in tumours
Aethox Therapeutics is a preclinical biotechnology company developing small-molecule drugs that help solid tumours respond to chemotherapy and other standard cancer treatments. Its lead approach targets heme oxygenase-1 (HO-1), an enzyme produced by tumour-associated macrophages that can block cancer-fighting T cells…
Generative AI platform for TCR therapy design and immune repertoire analysis
Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction…
Thermostable vaccine formulations delivered through microneedle patches
Microneedle Solutions is a biotechnology company developing vaccine-containing microneedle patches for self-administration. Its platform combines a patented needle-array manufacturing process with vaccine-loaded matrices intended to protect biological payloads and enable delivery through the skin. The company has…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies,…
Immunomodulatory therapeutics for chronic autoimmune and inflammatory diseases
Kherion Technology is a biotechnology company developing immunomodulatory treatments for chronic autoimmune and inflammatory diseases. Its lead preclinical programme investigates a proprietary therapeutic composition intended to reduce chronic inflammation without broadly suppressing immune activity. A granted US…
Engineered patient cells for sustained therapeutic antibody production
Semper-B Therapeutics is a biotechnology company developing a cell-engineering platform intended to enable patients’ own cells to produce therapeutic antibodies over prolonged periods. The approach aims to achieve durable, precise modulation of immune activity by using engineered cells as a continuing source of…
UK commercial base for a rare metabolic disease biotech
Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases. The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease. The UK…
Clinical-stage therapeutics for advanced liver disease
Yaqrit is a clinical-stage biotechnology company developing treatments for patients with advanced liver disease, including cirrhosis and acute-on-chronic liver failure. Its pipeline includes an oral ammonia scavenger for hepatic encephalopathy, an extracorporeal liver support device, and a microbiome-based…
Allergen immunotherapies for hay fever and food allergy
Allergy Therapeutics is a commercial biopharmaceutical company developing, manufacturing and selling immunotherapies that address the underlying immune cause of allergic disease. Its marketed products, sold across Europe, include short-course subcutaneous treatments for pollen and other respiratory allergies,…
ECM-targeted drug discovery platform for fibrosis and solid tumours
Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery platform integrates one of the largest ECM bioarchives with AI and machine learning to identify disease-specific targets and biomarkers.…
Programmable cell-killing particle platform for targeted therapeutic delivery
Granza Bio is a biotechnology company developing a cell-targeted delivery platform based on supramolecular attack particles, naturally occurring structures used by cytotoxic T cells and natural killer cells to deliver lethal payloads with precision. The company is engineering programmable versions of these particles,…
In vitro biology CRO for immunology and oncology drug discovery
BioMedha is a pre-clinical contract research organisation specialising in in vitro biology for early-stage drug discovery. The company provides assay development, target validation, compound screening, and mechanism of action studies across immunology, oncology, immuno-oncology, and inflammation therapeutic areas.…
Specialist distributor of transplant diagnostics and molecular biology products
VH Bio is a specialist distributor of life science research and diagnostic products serving the United Kingdom and Republic of Ireland. The company focuses on four areas: transplant and HLA diagnostics, molecular biology, immunology, and cell biology. Its portfolio of approximately 10,000 products is sourced from…
Engineered T cell receptor therapies for solid tumour cancers
Adaptimmune is a clinical-stage biopharmaceutical company developing engineered T cell receptor therapies targeting solid tumours. The company's T-cell platform engineers T cell receptors with enhanced affinity for cancer-associated antigens, enabling immune recognition of tumour cells that evade conventional…